Wu Xiaowu, Darlington Daniel N, Cap Andrew P
Blood Research, United States Army Institute of Surgical Research, Fort Sam Houston, Texas; and the Department of Surgery, University of Texas Health Science Center, San Antonio, Texas
Blood Research, United States Army Institute of Surgical Research, Fort Sam Houston, Texas; and the Department of Surgery, University of Texas Health Science Center, San Antonio, Texas.
Am J Physiol Regul Integr Comp Physiol. 2016 Feb 15;310(4):R323-9. doi: 10.1152/ajpregu.00401.2015. Epub 2015 Dec 2.
The purpose of this study was to determine whether trauma-induced coagulopathy is due to changes in 1) thrombin activity, 2) plasmin activity, and/or 3) factors that stimulate or inhibit thrombin or plasmin. Sprague-Dawley rats were anesthetized with 1-2% isoflurane/100% oxygen, and their left femoral artery and vein were cannulated. Polytrauma included right femur fracture, and damage to the small intestines, the left and medial liver lobes, and right leg skeletal muscle. Rats were then bled 40% of blood volume. Plasma samples were taken before trauma, and at 30, 60, 120, and 240 min. Polytrauma and hemorrhage led to a significant fall in prothrombin levels. However, circulating thrombin activity did not change significantly over time. Antithrombin III and α2 macroglobulin fell significantly by 2 h, then rose by 4 h. Soluble thrombomodulin was significantly elevated over the 4 h. Circulating plasmin activity, plasminogen, and D-dimers were elevated for the entire 4 h. Tissue plasminogen activator (tPA) was elevated at 30 min, then decreased below baseline levels after 1 h. Plasminogen activator inhibitor-1 was significantly elevated at 2-4 h. Neither tissue factor pathway inhibitor nor thrombin activatable fibrinolysis inhibitor changed significantly over time. The levels of prothrombin and plasminogen were 30-100 times higher than their respective active enzymes. Polytrauma and hemorrhage in rats lead to a fibrinolytic coagulopathy, as demonstrated by an elevation in plasmin activity, D-dimers, and tPA. These results are consistent with the observed clinical benefit of tranexamic acid in trauma patients.
1)凝血酶活性;2)纤溶酶活性;和/或3)刺激或抑制凝血酶或纤溶酶的因子。将Sprague-Dawley大鼠用1-2%异氟烷/100%氧气麻醉,然后将其左股动脉和静脉插管。多发伤包括右股骨骨折以及小肠、左肝中叶和右下肢骨骼肌损伤。然后将大鼠放血至血容量的40%。在创伤前以及创伤后30、60、120和240分钟采集血浆样本。多发伤和出血导致凝血酶原水平显著下降。然而,循环凝血酶活性并未随时间发生显著变化。抗凝血酶III和α2巨球蛋白在2小时时显著下降,然后在4小时时上升。可溶性血栓调节蛋白在整个4小时内显著升高。循环纤溶酶活性、纤溶酶原和D-二聚体在整个4小时内均升高。组织纤溶酶原激活物(tPA)在30分钟时升高,然后在1小时后降至基线水平以下。纤溶酶原激活物抑制剂-1在2-4小时时显著升高。组织因子途径抑制剂和凝血酶激活的纤维蛋白溶解抑制剂均未随时间发生显著变化。凝血酶原和纤溶酶原的水平比其各自的活性酶高30-100倍。大鼠的多发伤和出血导致纤维蛋白溶解型凝血病,纤溶酶活性、D-二聚体和tPA升高证明了这一点。这些结果与氨甲环酸在创伤患者中观察到的临床益处一致。